Use of Bortezomib in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia

Treating relapsed /refractory pediatric acute lymphoblastic leukemia (ALL), in developing countries, is a challenge. Novel options with reasonable efficacy /toxicity profile are needed.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Adriana Bello, Rossana Cortez, Maylu Collazo Source Type: research